Certara Inc
CERT
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
25.5% upsideUndervalued by 25.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.08 Billion |
|---|---|
| Enterprise Value | $1.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.49 |
| Outstanding Shares | 157,754,647 |
Return
| Return on Equity | -1.48% |
|---|---|
| Return on Assets | -1.01% |
| Return on Invested Capital | 3.04% |
Valuation & Multiples
| P/E Ratio | -72.91 |
|---|---|
| PEG | 25.6 |
| Price to Sales | 3.49 |
| Price to Book Ratio | 1.16 |
| Enterprise Value to Revenue | 2.43 |
| Enterprise Value to EBIT | 24.82 |
| Enterprise Value to Net Income | -68 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0289▲ 2.89% |
|---|---|
| Total Calls | 393,800▲ 553.07% |
| Total Puts | 11,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.99%▼ 7.86% |
|---|---|
| Total Invested | $768.54M▼ 40.80% |
| Investors Holding | 257▲ 1.00% |
ESG Score
No data
About Certara Inc
300 employeesCertara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the ...
Relevant Senate Committees
Controls Medicare/Medicaid drug pricing policy and tax credits for R&D. Legislation like the Inflation Reduction Act impacts the financial health and R&D spending of Certara’s entire client base.
Determines the funding levels for the FDA and NIH. Any shifts in discretionary spending for these agencies directly impact Certara's public sector contracts and its clients' R&D budgets.
Directly oversees the FDA and NIH. Since Certara's software is used by the FDA and 90% of novel drug approvals, changes in FDA regulatory science policy are material to Certara.